4,5,6,7-tetrabromo-2-azabenzimidazole has been researched along with cyclosporine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartenschlager, R; Cecchetti, V; Coelmont, L; Easmon, J; Herdewijn, P; Leyssen, P; Mittendorfer, H; Neyts, J; Paeshuyse, J; Puerstinger, G; Tabarrini, O; Vliegen, I | 1 |
| Aiello, G; Kobeissy, F; Kurup, M; Lin, F; Torres, I; Wang, KK; Yadikar, H; Yang, Z; Yost, R | 1 |
2 other study(ies) available for 4,5,6,7-tetrabromo-2-azabenzimidazole and cyclosporine
| Article | Year |
|---|---|
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
Topics: Antiviral Agents; Cell Line, Tumor; DNA Helicases; Enzyme Inhibitors; Hepacivirus; Humans; Microbial Sensitivity Tests; Protease Inhibitors; Replicon; RNA-Dependent RNA Polymerase; Virus Replication | 2008 |
Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.
Topics: Animals; Cell Line; Cyclosporine; Glycogen Synthase Kinase 3; Lithium Chloride; Mice; Models, Biological; Okadaic Acid; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Rats; Tauopathies; Triazoles | 2020 |